NIKKEI 225
27,641.83-139.19(-0.50%)HANG SENG
26,194.82-40.98(-0.16%)CRUDE OIL
70.23-0.33(-0.47%)GOLD FUTURES
1,813.40-8.80(-0.48%)DOW
35,116.40+278.24(+0.80%)BTC-GBP
27,585.76-724.13(-2.56%)
Gain Therapeutics, Inc. (GANX)
| Previous close | 8.05 |
| Open | 8.06 |
| Bid | 7.75 x 1000 |
| Ask | 10.50 x 1100 |
| Day's range | 7.96 - 8.16 |
| 52-week range | 7.64 - 17.93 |
| Volume | 5,188 |
| Avg. volume | 29,217 |
| Market cap | 95.013M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 30.00 |
- Globe Newswire
Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference
BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel allosteric binding sites on proteins responsible for neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the BTIG Virtual Biotechnology Conference being held on August 9 – 10. BTI
- Simply Wall St.
What Percentage Of Gain Therapeutics, Inc. (NASDAQ:GANX) Shares Do Insiders Own?
A look at the shareholders of Gain Therapeutics, Inc. ( NASDAQ:GANX ) can tell us which group is most powerful...
- Globe Newswire
Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders
Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lysosomal Storage DiseasesBETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced the publication of two PCT patents. PCT/IB2020/061158 and PCT/IB2020/0611156 are directed at compounds targeting misfold
